Paper Presentation Modes:

1. Present Paper in the Conference Venue.
2. Skype/Video/Zoom presentation will also be possible if the author is unable to attend the conference.

Paper Categories: The ICOSAM will accept two categories of papers:

[ I ]: Full Length Reseach Papers

[ II ]: Poster Presentations (Work in Progress/Ideas/Future Work/Papers).

For more details and journals links, please visit: Submission Page/

1. – All accepted and presented papers will be published in the Conference Proceeding and in well indexed journals.
2. – Authors of Selected papers will be invited to submit an extended version of their works (with at least 40% extension) for potential publication (Special issues and Regular) in indexed international journals.

Papers must be unpublished and original. Double submissions are strictly disallowed. All papers will undergo a rigorous peer-review process and will only be considered for publication if favorable decision is given by the subject matter experts conducting peer-review.

All submissions (Papers and Posters) will be made using EASYCHAIR at; Paper Submission Link or email at : icosam23@gmail.com

You can download Paper Template by clicking below:

Paper-Template

You can download Poster Template by clicking below:

Poster-Template

1. Pharmaceutical Marketing in the Digital Era.
2. Improving the Clinical Practices Guidelines.
3. Interaction and Communication between Physician, Veterinarian, Pharmacists and Stakeholders.
4. Use of IT in Pharma Practice.
5. Prevalnce of Using Non-prescribed Medications in Economically Deprived Rural Population of Pakistan.
6. Misuse of Sedative and Abuse of Drugs by Vocalist Groups.

Dr. John, Professor, Department of Life and Natural Sciences, Alabama A & M University, United States.

Dr. Khoa D. Nyugen, Associate Professor, Department of Sciences, University of South Australia, Australia.

Prof. Dr. Raziq Yaqub an Associate Professor in the EE&CS; Department, Alabama A&M; University, USA, and a Research Professor at NASA Gelnn Research Center, Cleveland, OH. He earned a Ph.D. in Wireless Communication from Keio University, Japan, and an MBA in Marketing from Fairleigh Dickenson University, New Jersey, USA. He is an inventor of technologies in Cybersecurity of Financial Technologies, Wireless Communications, Smart Grid, and Connected Electric Vehicles. He has 45 issued patents, and is a recipient of the “Inventor of the Year Award-2014” from the Inventors Hall of Fame, New Jersey. He received an award of “Excellence in Scholarship and Research 2019” from the President of his university, an award of “Innovator Young Faculty,” an award of “Outstanding Engineering Educator” from the Dean of his college, and “Outstanding Engineer 2020” award from IEEE region-3. He remained an Executive Director of Toshiba America Research, New Jersey, to lead 4G/LTE, Department head of NIKSUN University, Princeton, New Jersey, to lead Cybersecurity, and Director of Global R&D; of Tecvox, Huntsville, AL, USA, to lead wireless charger and media hubs for the automotive industry. He also remained Sr. Consultant to the State of New Jersey to secure an $87M grant, a spokesperson of the Department of Homeland Security in 3GPP”, an invited Researcher in NASA Research Center, Cleveland, Ohio, and an inventor for Wells Fargo, USA. He also remained Chairman and contributor to standards organizations such as 3GPP, IEEE, WiMAX, MWIF, OMA, Lead Member for ABET accreditation, Chairman Academic Standards Committee, Chair IEEE Membership Development, Evaluator for technical papers, Ph.D. theses, patents, and grant proposals, Vice Chairman of IEEE Southeast Conference 2019, organizer of numerous international conferences, Invited/Keynote speaker, Panel Moderator/Resource Person in international events. He is a Senior Member of IEEE. He communicates in English, Japanese, Hindi, and Urdu, and has 25 years of experience in the industry, government, and academia.

Topic: Role of Gut Biota and Diet with Metabolic Endotoxemia in Mice. Metabolic endotoxemia is a state of increased level of lipopolysaccharides (LPS) or endotoxins in the blood. During this condition, proinflammatory molecules such as interleukin-1, interleukin-6, tumor necrosis factors (TNF-α) are increasingly expressed. This study was aimed to investigate the effect of cultured gut microbiota (GM) from obese humans coupled HFD in inducing metabolic endotoxemia in humanized mice. In total, 30 strains were isolated from 10 stool samples of obese patients. Following morphological and biochemical characterization, 16S rRNA gene sequencing of six abundant isolates identified these Klebsiella aerogenes, Levilactobacillus brevis, Escherichia coli, Staphylococcus aureus, Bacillus cereus and Bacillus subtilis (MZ052089- MZ052094). In vivo trial using above isolates, known as human gut microbiota (HGM), was performed for six months. Sixteen mice were distributed into four groups i.e., G1 (control) mice fed with chow diet, group 2 (G2) with HFD, group 3 (G3) with HFD + HGM and group 4 (G4) with chow diet + HGM. Body mass index (BMI) and plasma endotoxins were measured pre and post experiment. In vivo study revealed that HFD + HGM caused significant increase (3.9 g/cm at 20 weeks) in the body weight and BMI (0.4g/cm post experiment) of G3 mice compared to the other groups. One way ANOVA showed significantly higher level of endotoxins (2.41, 4.08 and 3.7 mmol/l) in mice groups G2, G3 and G4, respectively, indicating onset of metabolic endotoxemia. Cecal contents of experimental mice groups showed a shift in microbial diversity as observed by all isolates belonging to either Firmicutes or Bacteriodetes phyla, respectively. In conclusion, current study reported that minor alteration in GM composition through HFD feeding and cultured GM transfer has significant impact in development of metabolic endotoxemia, possibly via modified intestinal permeability.

Topic: Research Methodology - Defining and Redefining.

TECHNICAL SPONSORS